NASDAQ:BNOX Bionomics (BNOX) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free BNOX Stock Alerts $0.95 +0.02 (+2.16%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.91▼$0.9550-Day Range$0.92▼$1.2552-Week Range$0.87▼$6.41Volume25,115 shsAverage Volume194,215 shsMarket Capitalization$7.73 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Bionomics alerts: Email Address Bionomics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside850.5% Upside$9.00 Price TargetShort InterestHealthy3.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.59) to ($4.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.23 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBionomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBionomics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.17% of the outstanding shares of Bionomics have been sold short.Short Interest Ratio / Days to CoverBionomics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bionomics has recently increased by 343.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBionomics does not currently pay a dividend.Dividend GrowthBionomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNOX. Previous Next 0.9 News and Social Media Coverage News SentimentBionomics has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.Search InterestOnly 6 people have searched for BNOX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bionomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Bionomics is held by insiders.Percentage Held by InstitutionsOnly 15.90% of the stock of Bionomics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bionomics are expected to decrease in the coming year, from ($2.59) to ($4.17) per share.Price to Book Value per Share RatioBionomics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Bionomics Stock (NASDAQ:BNOX)Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Read More BNOX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNOX Stock News HeadlinesApril 17, 2024 | finance.yahoo.comBionomics Limited (BNOX) Stock Historical Prices & Data - Yahoo FinanceMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Bionomics’ BNC210 Following Promising PTSD Study ResultsApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 21, 2024 | msn.comBionomics Reveals Detailed Data From PTSD Trial, Stock SoarsMarch 21, 2024 | globenewswire.comBionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress DisorderMarch 20, 2024 | finance.yahoo.comBionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)February 22, 2024 | globenewswire.comBionomics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 22, 2024 | benzinga.comBionomics Stock (NASDAQ:BNOX), Short Interest ReportApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…January 22, 2024 | finanznachrichten.deBionomics Ltd: Bionomics Provides a Review of 2023 and of 2024 PlansJanuary 22, 2024 | finance.yahoo.comBionomics Provides a Review of 2023 and of 2024 PlansDecember 7, 2023 | morningstar.comBionomics Ltd ADR BNOXDecember 6, 2023 | finance.yahoo.comBionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual MeetingDecember 4, 2023 | ca.finance.yahoo.comBionomics Limited (BNOX)October 19, 2023 | benzinga.comBionomics Meets The FDA: Lead Drug Candidate For Social Anxiety Heads To Phase 3October 3, 2023 | markets.businessinsider.comPromising Progress of BNC210 Bolsters Buy Rating on Bionomics Amidst Rising Interest in SAD TreatmentsSeptember 30, 2023 | finance.yahoo.comBionomics Full Year 2023 Earnings: AU$3.60 loss per share (vs AU$0.016 loss in FY 2022)September 29, 2023 | finance.yahoo.comBionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%September 29, 2023 | msn.comBionomics’ stock rallies 300% after company reports positive results in trial of PTSD treatmentSeptember 28, 2023 | markets.businessinsider.comBionomics' Victory - Analysts Note Optimism Around Promising Prospects for PTSD TreatmentSeptember 28, 2023 | finance.yahoo.comBionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)September 28, 2023 | msn.comWhy Is Stress Disorder Focused Bionomics Stock Trading Higher Today?September 28, 2023 | investorplace.comWhy Is Bionomics (BNOX) Stock Up 347% Today?September 4, 2023 | nasdaq.comBionomics Limited American Depository Shares (BNOX)July 31, 2023 | finanznachrichten.deBionomics Ltd: Quarterly Activities and Cashflow ReportJune 15, 2023 | finance.yahoo.comBionomics to Present at Upcoming June Investor ConferencesMay 30, 2023 | finance.yahoo.comBionomics Announces Upcoming Poster Presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual MeetingSee More Headlines Receive BNOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Next Earnings (Estimated)4/24/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BNOX CUSIPN/A CIK1191070 Webwww.bionomics.com.au Phone088-150-7400FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+850.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio3.81 Quick RatioN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales772.67 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.35Miscellaneous Outstanding Shares8,160,000Free Float8,038,000Market Cap$7.73 million OptionableNot Optionable Beta-0.09 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Spyridon Papapetropoulos M.D. (Age 51)Ph.D., CEO, President & Director Comp: $498.92kMr. Adrian Hinton BEC (Age 71)F.C.A., Financial Controller Comp: $193.97kMr. Timothy M. Cunningham CPA (Age 61)M.B.A., Chief Financial Officer Prof. Paul Rolan D.C.P.S.A.F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical NeuroscienceDr. Julie Kerner Ph.D.Senior Vice President of Business OperationsMs. Suzanne Irwin B.Com.FCIS, Company SecretaryMore ExecutivesKey CompetitorsTFF PharmaceuticalsNASDAQ:TFFPBiofronteraNASDAQ:BFRIChemomab TherapeuticsNASDAQ:CMMBASLAN PharmaceuticalsNASDAQ:ASLNPasithea TherapeuticsNASDAQ:KTTAView All Competitors BNOX Stock Analysis - Frequently Asked Questions Should I buy or sell Bionomics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNOX shares. View BNOX analyst ratings or view top-rated stocks. What is Bionomics' stock price target for 2024? 2 Wall Street research analysts have issued twelve-month price targets for Bionomics' shares. Their BNOX share price targets range from $8.00 to $10.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 850.5% from the stock's current price. View analysts price targets for BNOX or view top-rated stocks among Wall Street analysts. How have BNOX shares performed in 2024? Bionomics' stock was trading at $1.48 on January 1st, 2024. Since then, BNOX shares have decreased by 36.0% and is now trading at $0.9469. View the best growth stocks for 2024 here. Are investors shorting Bionomics? Bionomics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 258,400 shares, an increase of 344.0% from the March 15th total of 58,200 shares. Based on an average trading volume of 213,800 shares, the short-interest ratio is presently 1.2 days. View Bionomics' Short Interest. When is Bionomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our BNOX earnings forecast. When did Bionomics IPO? Bionomics (BNOX) raised $20 million in an initial public offering on Thursday, December 16th 2021. The company issued 1,622,000 shares at $12.35 per share. How do I buy shares of Bionomics? Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BNOX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
